ABSTRACT We have reported previously that thromboxane A2/prostaglandin (PG)H2 and serotonin independently mediate the occurrence of cyclic flow variations (CFVs) in a canine preparation of severe coronary artery narrowing. This may be due to an effect of these substances on platelets and/or the vascular wall. We tested the hypothesis that there is a cooperative effect between thromboxane A2/PGH2 and serotonin receptor stimulation in the development of CFVs in this animal preparation. After placement of a hard plastic cylindrical constrictor around the left anterior descending coronary artery, CFVs develop and are characterized by repetitive cycles of declines in coronary blood flow and abrupt increases in flow. In a control group of dogs, CFV frequency (cycles/hour) and severity (lowest coronary blood flow just before its restoration) did not change significantly over a 3 hr interval. In a second group of dogs, CFVs were established after constrictor placement, abolished with the serotonin (5HT2) receptor antagonist ketanserin, and reestablished by the continuous infusion of serotonin into the left atrium. Serotonin-induced CFVs were then abolished with a thromboxane A2/PGH2 receptor antagonist, SQ29,548, or a thromboxane synthetase inhibitor, dazoxiben (UK37,248). The relative specificity of the respective antagonists, SQ29,548 and ketanserin, was determined in canine platelets and rat aortic vascular strips. No significant cross-reactivity between ketanserin and SQ29,548 was found. Thus, the data obtained in these studies demonstrate a cooperative interaction between thromboxane A2/PGH2 and serotonin S2 receptors that contributes to the development of CFVs in this experimental preparation. Circulation 76, No. 4, 952-959, 1987 
and ultimately result in irreversible aggregation of the activated platelets.9 The present study was designed to test the hypothesis that stimulation of both thromboxane A2/PGH2 and 5HT2 receptors on platelets and/or within the coronary vascular wall interact cooperatively in leading to the development of transient flow reductions in a canine preparation of severe coronary artery stenosis. Methods Surgical preparation. The experimental preparation used was one originally described by Folts et al.'0 Fifty-one male mongrel dogs (18 to 33 kg) were anesthetized with sodium pentobarbital (30 mg/kg) and ventilated with room air. Catheters were placed in the common carotid artery and jugular vein for arterial pressure measurement and fluid administration, respectively. A thoracotomy was performed in the fifth left intercostal space of each dog and the heart was suspended in a pericardial cradle. A segment of left anterior descending coronary artery (LAD) was gently dissected free from surrounding tissue and a pulsed Doppler flow probe (Dr. C. J. Hartley, Houston)" was positioned around the LAD proximally but adjacent to where the coronary artery constrictor would be placed. Arterial blood gases and body temperatures were maintained within normal physiologic limits.
Experimental protocols. At the conclusion of the surgical instrumentation, dogs were allowed to stabilize for 30 min. Control hemodynamics, including systolic and diastolic blood pressures, heart rates, and mean and phasic coronary blood flow velocities, were recorded continuously on an eight-channel recorder (Hewlett-Packard, model 7758). A plastic cylindrical constrictor was placed around the LAD, resulting in a luminal diameter that reduced control phasic blood flow velocity by approximately 50%; this degree of coronary artery constriction was required to attenuate reactive hyperemia after a 10 sec coronary artery occlusion. Cyclic flow variations (CFVs) normally began within 15 min of constrictor placement. Animals were divided into two groups for this study.
Group I -control animals. CFV frequency (number of CFVs per hour), severity (nadir of coronary blood flow velocity), and hemodynamics were monitored continuously for 3 hr in 28 dogs. No drug intervention was used in these animals.
Group II. CFVs were established in 23 dogs. Once CFV frequency and severity were reproducible, CFVs were documented for a 30 min period. Ketanserin, a SHT2 receptor antagonist (Janssen Pharnaceutical, Beerse, Belgium), was dissolved in warm saline to make a I mg/ml solution and was administered into the left atrium at doses beginning at 0.1 mg/kg and increasing at 15 min intervals to 0.25, 0.5, 0.75, 1.0, 1.5, and 2 mg/kg until CFVs disappeared.
Serotonin (5-hydroxytryptamine ergotamine sulfate, 5-HT, Sigma Chemical Co., St. Louis), was dissolved in normal saline, and was then infused continuously into the left atrium of dogs in which CFVs had been abolished for 60 min (Harvard infusion/withdrawal pump, model 600, Harvard Apparatus Co., Natick, MA). Serotonin infusion was begun at 0.1 mg/min and increased to 0.25, 0. Hemodynamic changes. There were several significant hemodynamic changes observed during the 3 hr of cyclic flows in the control (group I) dogs. Heart rates declined significantly immediately after CFVs were initiated (table 1) . Heart rates declined still further during the second and third hours of CFVs in this group, an effect likely due to the length of time under anesthesia. A slight but significant elevation in mean arterial pressures was observed during the first hour of CFVs. Heart rates also declined before ketanserin treatment in group II dogs, which was similar to the changes observed in group I control dogs.
Mean arterial pressures and heart rates declined significantly with the administration of ketanserin (group II-A and II-B animals), an effect that has been reported.8 Mean arterial pressure was not significantly changed during serotonin infusion after ketanserin, but heart rates were significantly lower than those after ketanserin alone (group 11-A dogs). Mean arterial blood pressure was unaltered during treatment with dazoxiben (group II-A 1), but heart rates were lower than those observed during the serotonin infusions. Heart rates rose during administration of SQ29,548 (group II-A2), but systemic blood pressures declined. These hemodynamic effects were not as pronounced in group II-B 1 and B2 dogs, probably due to the absence of serotonin.
CFV frequency and severity Control dogs (group I). In the 28 dogs of group I in which CFVs were initiated and continued for a 3 hr period with no drug interventions, the number of CFVs (measured in cycles per hour) did not change significantly throughout the 3 hr time interval (10.4 ± 0.6, hour 1; 9.7 + 0.5, hour 2; 10.3 ± 0.5, hour 3). The severity of the flow reduction before flow restoration in each cycle, defined as the nadir of the CFV, also was not significantly different during the 3 hr period of CFVs (7 + 2% of control flow, hour 1; 8 + 2, hour 2; 8 ± 2, hour 3).
Serotonin-induced CFVs (group II). The 23 dogs in group II had an initial CFV frequency of 4.87 ± 0.34 cycles for a 30 min period and a mean coronary blood flow Canine platelets failed to aggregate in response to either U46619 or serotonin alone. However, subaggregatory concentrations of epinephrine (10 ,uM) sensitized canine platelets to U46619 and serotonin. Serotonin, at 10 ,uM concentration, caused maximal aggregation responses in epinephrine-primed platelets. The slope, or initial rate of aggregation, was 44% per minute.
SQ29,548 inhibited U46619-induced platelet aggre- figure  3, A) . SQ29,548 inhibited serotonin-induced platelet aggregation by 50% only at the highest concentration tested, which was 1000 ,M (IC50 = 1000 gM) ( figure   3, B) . Therefore, SQ29,548 is approximately 300,000 times more active as a thromboxane-receptor antagonist than as a serotonin antagonist in canine platelets.
Ketanserin inhibited serotonin-induced aggregation of epinephrine-primed canine platelets with an IC50 of 14 nM ( figure 3, B) . However, the IC50 for ketanserin inhibition of U46619-induced platelet aggregation was 100 ,uM ( figure 3, A) . Thus, ketanserin is approximately 7000 times more active as a serotonin antagonist than as a thromboxane antagonist in canine platelets. Plasma epinephrine. Plasma epinephrine concentrations were extremely low (<10 pg/ml) immediately before serotonin infusion and 30 min after serotonin restoration of CFVs in all five animals tested.
Discussion
The present study was designed to test the hypothesis that activation of both 5HT2 and thromboxane A2/PGH2 receptors on platelets and/or in the vascular wall occurs when cyclic flow variations develop in a CIRCULATION canine preparation with a severe coronary artery stenosis and endothelial damage. We have reported previously that the concentration of serotonin is elevated at the site of a severe coronary artery stenosis, probably due to the large platelet mass adherent to the vessel wall,7 and that pharmacologic blockade of 5HT2 receptors with ketanserin eliminates CFVs in most animals. 8 We also reported in another group of animals that thromboxane A2 synthesis is increased and prostacyclin synthesis is decreased in the vascular tissue at the site of the coronary artery stenosis.6 Furthermore, we found that both a thromboxane synthetase inhibitor, dazoxiben (UK37,248) and thromboxane-receptor antagonists (SQ29,548 or SQ28,688) were effective in eliminating CFVs in a majority of animals. 4 5 The data obtained in the present study demonstrate that a continuous serotonin infusion restores CFVs after ketanserin blockade of CFVs. Arterial hypotension after administration of ketanserin may have been expected to reflexly elevate circulating epinephrine levels, potentiating the effect of serotonin on platelet aggregation. Plasma epinephrine concentrations were very low during an initial period of CFVs and remained extremely low after administration of ketanserin and subsequent CFV restoration with serotonin. The observation has been made in this study and others7' 8 that hypotension caused by ketanserin administration does not result in an expected reflex tachycardia, indicating that normal bororeflex activity is not functioning. There is evidence to suggest, however, that ketanserin decreases preganglionic nerve activity'5 and blocks reflexly induced changes in blood pressure and heart rate, probably due to 5HT2 receptor blockade in the vasomotor center. 16 Since the adrenal medulla is anatomically and functionally a sympathetic ganglia, 17 this may explain the lack of reflexly mediated release of epinephrine.
Serotonin-restored CFVs were abolished by the inhibition of thromboxane synthesis or by the blockade of thromboxane A2/PGH2 receptors. These data confirm and extend our initial observations that blockade of either the 5HT2 or thromboxane A2/PGH2 receptor abolishes CFVs in this preparation in most cases. These data suggest that pharmacologic blockade of either 5HT2 or thromboxane A2/PGH2 receptors or diminishing the synthesis of thromboxane A2 prevents the necessary platelet and vascular wall interaction for CFVs to occur.
The range in the doses of antagonists used to abolish CFVs in group II dogs varied considerably from animal to animal. This may be due to variability in the extent of stenosis and extent of vascular damage inflicted on the artery before initiation of CFVs. In addition, variation in the amount of released mediators during platelet activation and receptor sensitivity to released mediators may also be factors. Potentially, the intensity of the response of the vascular wall to the released mediators also contributes to the severity of platelet/vessel wall interaction and, therefore, to the dose of antagonist required to abolish this response. The availability of other mediators and the platelet sensitivity to these potentially synergistically acting mediators may also play a role in the concentrations of antagonist necessary to eliminate CFVs. In those dogs in which the initial thromboxane A2/PGH2 or 5HT2 receptor blockade did not abolish CFVs, addition of the thromboxane A2 synthetase inhibitor or the receptor-blocking agent abolished CFVs in all cases. These data suggest that pharmacologic blockade of both thromboxane A2/PGH2 and serotonin S2 receptor types is an effective way of restoring a uniform flow pattern in stenosed arteries.
An alternate explanation for these data is a lack of specificity of the drugs used. This point was investigated in a series of studies. SQ29,548 ia s very selective and potent thromboxane A2/PGH2 antagonist in the family of compounds with the 7-oxabicyclo[2.2.1] heptane nucleus identified thus far. It does not alter the activities of thromboxane synthetase, cyclooxygenase, or adenylate cyclase, and it does not possess thromboxane A2 agonist properties.'2 18 SQ29,548 was more than 300,000 times more effective in inhibiting U466 19-induced canine platelet aggregation than serotonin-induced aggregation. Ogletree et al. ' 2 reported previously that SQ29,548 has no detectable influence on serotonin-induced contraction of rat aorta, but competitively inhibits U46619-induced contractions in aortic strips obtained from the rat.
The specificity of ketanserin in blocking both vascular and platelet 5HT2 receptors has been well documented.'9-22 Although it also is known to possess a receptor antagonist properties, 19 previous data from our laboratory have demonstrated that the administration of the selective al-adrenergic antagonist prazosin does not diminish the frequency of CFVs in this canine preparation.8 This suggests that it is ketanserin's 5HT2 antagonistic properties and not al-blockade that is responsible for eliminating CFVs.8 In the present study, we verified that ketanserin is a poor antagonist of the vascular or platelet thromboxane A2/PGH2 receptor. Ketanserin was more than 7000 times more effective in antagonizing serotonin-induced than U46619-induced aggregation of canine platelets. Furthermore, ketanserin is an excellent inhibitor of sero-tonin-induced aortic smooth muscle contraction, '9 23 but the results from this study show that is does not influence contractions of isolated rat aortic muscle induced by the thromboxane mimetic U46619.
Platelet aggregation and adherence of platelets to a vascular wall in vivo probably occur most commonly as the result of the presence of more than one aggregating agent.9' 24 The amplifying effect of serotonin on other mediators of platelet aggregation was first described by O'Brien25 and later by Baumgartner and Born.26 Serotonin potentiates ADP-, collagen-and epinephrine-induced platelet aggregation in a synergistic manner, and this effect is blocked by ketanserin. 22 The secretion of contents of the a-granules and arachidonic acid liberation from membrane phospholipids induced by collagen are also potentiated by serotonin, and this effect is inhibited by ketanserin.27 Serotonin also amplifies contractions induced by thromboxane A2 in canine coronary arteries, and this potentiation may be blocked by ketanserin.23, [27] [28] [29] Agonist-receptor interaction on platelet membranes results in release and elevation of cytoplasmic Ca+ + which in turn initiates a series of reactions, including further release of Ca + + from intracellular stores.24 A critical concentration of cytoplasmic Ca+ + may be necessary to initiate secretion from the a-and dense granules and activation of phospholipase A2, which liberates arachidonic acid from the membrane.24 Serotonin can mobilize both intracellular and extracellular Ca ++ stores in vascular smooth muscle. [30] [31] [32] In summary, the results from this study show that occupation of both thromboxane A2/PGH2 and 5HT2 receptors on the platelet and/or in the vascular wall may be necessary to provide sufficient platelet/vessel wall interaction to lead to CFVs in severely narrowed and endothelially injured canine coronary arteries. CFVs can be eliminated in 70% to 75% of dogs by pharmacologic blockade of either the thromboxane A2/PGH2 or the 5HT2 receptor. Even though thromboxane A2/PGH2 receptor antagonists did not inhibit serotonininduced platelet aggregation and the 5HT2 antagonists did not inhibit U46619-induced aggregation in vitro, serotonin-induced CFVs were eliminated with a thromboxane A2/PGH2 receptor antagonist or thromboxane A2 synthesis inhibitor. These results suggest that in a majority of dogs, stimulation of both thromboxane A2/PGH2 and 5HT2 receptors is necessary to induce sufficient interaction to lead to CFVs and that receptor antagonism for either agonist is sufficient to interrupt CFVs. In a minority of dogs, stimulation of both receptor types causes CFVs and requires antagonism of agonist binding to both 5HT2 and thromboxane A2/PGH2 receptors to restore a normal flow pattern through the narrowed artery. The relative contributions of platelet and/or vascular receptor stimulation to the development of CFVs is unclear and will require further study.
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